Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review highlights that Wedelolactone, a compound in Eclipta prostrata, appears to be a potent antioxidant and selective modulator of proteins linked to chronic diseases, suggesting further research into its pharmacological effects is warranted according to the examined data.

This review found that combined oral contraceptives and spironolactone are effective treatments for adult acne in women, but noted that oral contraceptives increase the risk of venous thromboembolism and require individual risk assessment before use.

This study found that finasteride users had a very low rate of psychiatric side effects, with no significant increase in BPH patients and a slight increase in anxiety and depression among AGA patients.

This review discusses spironolactone as an effective and potentially safer treatment for androgenic alopecia, particularly when used with minoxidil, but calls for more high-quality clinical trials.

This study found that scabies was the most common skin condition among children up to 15 years old at a Karachi hospital in 2005.

This study found that the combination therapy of Flosin and Prostamol Uno over nine years was well tolerated and equally effective in managing benign prostatic hyperplasia symptoms as the combination of doxazosin and finasteride, with fewer adverse events reported.

This source reports that clascoterone cream has been approved in the U.S. for treating acne vulgaris in patients aged 12 and older, suggesting it works by competing with dihydrotestosterone at androgen receptors to mitigate acne's effects.

This study reported that while no synthesized compounds surpassed finasteride in 5α-reductase inhibitory activity, certain 4-azasteroid-2-oximes exhibited notable inhibition.

This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.

This study reported that oral isotretinoin effectively stabilized frontal fibrosing alopecia in patients, which may help guide healthcare providers in managing this condition related to hair loss and self-esteem.

In this study, both finasteride and hydroxychloroquine were found to be equally effective, safe, and well-tolerated first-line treatments for frontal fibrosing alopecia in female patients, with no significant differences in efficacy between the two therapies over six months.

This case report describes a patient with lamotrigine-associated drug-induced hypersensitivity syndrome requiring prolonged and complex treatment, with observed complications including extensive alopecia areata and autoimmune thyroiditis.

This study found that testosterone replacement, with or without finasteride, did not lead to significant cognitive improvements over 36 months in healthy older men without prior cognitive impairment.

This study examined data from the FDA Adverse Event Reporting System and found that finasteride use is linked with both known and previously unlisted adverse events, such as erectile dysfunction and post-5α reductase inhibitor syndrome, with variations observed by age and sex.

This review discusses treatments for female acne, highlighting the effectiveness of low-dose oral contraceptives and noting their similar side effects to placebo; it reports no new clinical results.

This study found that chronic exposure to fadrozole or finasteride during frog development induced intersex individuals, which displayed different gene expression profiles depending on the chemical used.

This study found that finasteride treatment in male rats has lasting effects on depressive-like behavior, hippocampal neurogenesis, neuroinflammation, and gut microbiota composition even one month after discontinuation.

This study found that cyproterone acetate treatment improved quality of life and reduced anxiety and depressive symptoms in women with skin manifestations of hyperandrogenism.

In this randomized trial, metformin and pioglitazone both improved certain clinical and metabolic indices in women with PCOS, with pioglitazone showing potential as an alternate treatment for those intolerant to metformin.

This review provides an overview of the prevalence and management of side effects of mood-stabilizing drugs in bipolar disorder patients and reports no new clinical results.

This study found that administering melatonin for 12 weeks to women with PCOS significantly reduced hirsutism, testosterone, and inflammation markers, while enhancing antioxidant levels compared to a placebo.

In this study, oral prednisolone pulse therapy led to significant hair regrowth in some patients with extensive alopecia areata, whereas no improvement was seen in the placebo group.

This study reported that spironolactone at 200 mg/day significantly improved facial hair growth in women with hirsutism and showed a sustained reduction in ovarian androgens over one year.

In this study, the combination of metoprolol and spironolactone in patients with coronary heart disease and heart failure significantly improved cardiac function and reduced inflammation and oxidative stress markers compared to spironolactone alone, with better clinical efficacy and fewer adverse effects.

This article discusses Truman Plus Male Enhancement, a testosterone booster, emphasizing its potential benefits for sexual health and energy, but does not report any new clinical results.

This article highlights the lack of attention to the impact of polycystic ovarian syndrome on women's identity, mental health, and quality of life in India without offering new findings.

This study found that after 12 months of treatment with 5 mg of finasteride, patients with benign prostatic hyperplasia showed reduced prostate volume, DHT and PSA levels, and improved urinary flow rates and symptoms.

This review suggests that oral prednisolone pulse therapy and oral inosiplex may be effective for alopecia areata, but robust evidence from randomized controlled trials is lacking, highlighting the need for better-designed future studies.

This review of teriflunomide for relapsing-remitting multiple sclerosis examines its clinical and safety outcomes, finding it significantly reduces relapse rates and disability progression while being generally well-tolerated.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.